PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Aligned Genetics continues to expand revenue across its life science tools (LST) and molecular diagnostics (POCT) businesses, though widening quarter-to-quarter profit swings call for closer scrutiny of earnings quality.
Annual revenue rose for four straight years from KRW 13.75bn in 2022 to KRW 16.02bn in 2025, even as operating margin slipped from 20.7% to 15.3% over the same span.
After a net loss of KRW -117mn in Q2 2025, the company posted net profit for four consecutive quarters through Q2 2026, with Q2 2026 net income of KRW 1.75bn marking the largest in that window.
The business is built on cell-counting/imaging life science tools (LST) and cartridge-based molecular diagnostics (POCT), with a women's-health digital healthcare line also referenced in recent regulatory filings.
The company has secured GMP conformity certification for its molecular diagnostics manufacturing facility and a US patent related to its diagnostic cartridge technology, reinforcing its quality and technology infrastructure.
The valuation sits close to net asset value, and whether the recent four-quarter earnings recovery proves durable is a key point to watch.
Aligned Genetics was founded in 2008 as a technology venture developing and globally selling advanced life science research and diagnostic instruments and reagents, and it listed on KOSDAQ in 2016.
The company's business is split into two pillars: life science tools (LST) and molecular diagnostics (POCT), with the LST segment centered on automated cell counters and cell imaging equipment supplied to research institutes and hospitals.
Based on convergence technology, its core products include automated cell counting, tissue clearing and imaging, and digital cell imaging systems.
In recent years, revenue composition has consisted of equipment accounting for more than half of sales, consumables and related items making up most of the remainder, and a small contribution from rental income.
Its flagship next-generation automated cell counter, LUNA-III, was recognized as one of the 2025 Best New Life Sciences Product award winners by global scientific media platform SelectScience, following a similar award for its predecessor, LUNA-FX7, in 2020.
Its customer base is understood to include global pharmaceutical and research organizations such as Vertex Pharmaceuticals.
On the molecular diagnostics (POCT) side, the company has obtained GMP conformity certification for in-vitro diagnostic device manufacturing and secured a US patent related to an analyte-collecting device, a core component of its diagnostic cartridge.
Recent regulatory filings also reference a women's-health digital healthcare brand combining pregnancy, ovulation, menopause and hormone diagnostic kits with mobile-linked devices, suggesting portfolio diversification.
Separately, in another bio company's listing review process, Aligned Genetics was selected alongside Thermo Fisher Scientific, Revvity, and Mettler-Toledo as a comparable company, indicating the market places it in the same industry category as global life science instrument makers.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.9B | ₩300M | 6.6% |
| 2025Q3 | ₩3.9B | ₩500M | 14.0% |
| 2025Q4 | ₩4.3B | ₩1.1B | 25.9% |
| 2026Q1 | ₩3.6B | ₩200M | 6.3% |
| 2026Q2 | ₩4.4B | ₩600M | 14.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩13.8B | ₩2.8B | ₩2.3B | 20.7% | 8.1% | 27.9% |
| 2023 | ₩15.2B | ₩3.3B | ₩3.2B | 21.9% | 10.3% | 30.7% |
| 2024 | ₩15.8B | ₩2.8B | ₩4.1B | 17.6% | 11.6% | 24.7% |
| 2025 | ₩16B | ₩2.4B | ₩2.9B | 15.3% | 7.8% | 55.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue rose for four consecutive years, from KRW 13.75bn in 2022 to KRW 15.21bn in 2023, KRW 15.78bn in 2024, and KRW 16.02bn in 2025. Operating margin, however, peaked at 20.7% in 2022 and 21.9% in 2023 before declining for three straight years to 17.6% in 2024 and 15.3% in 2025.
Net income attributable to owners rose from KRW 2.33bn in 2022 to KRW 3.24bn in 2023 and KRW 4.13bn in 2024, before falling to KRW 2.91bn in 2025; the fact that 2024 net income exceeded operating profit (KRW 2.78bn) and 2025 net income also exceeded operating profit (KRW 2.44bn) suggests a meaningful contribution from non-operating items in both years.
On a quarterly basis, Q2 2025 revenue of KRW 3.92bn and operating profit of KRW 260mn nonetheless coincided with a net loss attributable to owners of KRW 117mn, pointing to a non-operating drag that quarter.
This was followed by a clear recovery, with net income of KRW 933mn in Q3 2025 and KRW 1.54bn in Q4 2025, before Q1 2026 revenue eased to KRW 3.64bn and operating profit to KRW 230mn while net income came in at KRW 418mn.
Q2 2026 saw revenue improve to KRW 4.35bn and operating profit to KRW 644mn, while net income expanded to KRW 1.75bn, the highest in the period shown, with the wide gap over operating profit again pointing to a sizable non-operating contribution.
Trailing four-quarter (Q3 2025 through Q2 2026) net income attributable to owners totaled KRW 4.64bn, indicating that quarterly profitability has stayed positive since emerging from the Q2 2025 loss.
Given the multi-year downtrend in operating margin, it remains important to distinguish whether future earnings quality stems from genuine operating improvement or continued reliance on non-operating items.
The life science tools industry that Aligned Genetics operates in is relatively insulated from economic cycles, and industry-wide performance has reportedly continued to improve even amid political instability and demand headwinds from high US tariffs.
The life science tools market the company serves is projected to grow from $8.383bn in 2024 to $13.462bn by 2032, driven in part by rising use of in-vitro diagnostic reagents for chronic and infectious disease testing.
The in-vitro diagnostics (IVD) market, the company's other pillar, was estimated at $78.7bn in 2023 and is forecast to grow at a 7.20% compound annual rate to $119.4bn by 2029.
Molecular diagnostics in particular plays an important role in cancer, genetic disease, and infectious disease testing, is expected to be among the fastest-growing segments from 2023 to 2029, and should see surging demand as personalized and precision medicine advance.
Within KOSDAQ, the company is classified under the medical and precision instruments sector, more specifically under medical equipment and services.
On the competitive front, Aligned Genetics has been grouped as a comparable company alongside global life science instrument majors such as Thermo Fisher Scientific, Revvity, and Mettler-Toledo, suggesting it competes in niche areas such as cell counting and imaging despite a vast scale disadvantage.
Domestically, the company drew attention as a COVID-19 diagnostic-kit theme stock during the pandemic, but the broader diagnostics industry's exports and earnings have since reset closer to pre-pandemic levels.
The company has secured GMP conformity certification for its molecular diagnostics manufacturing facility, making the pace of mass production and revenue conversion for related cartridge products a key point to watch.
Having obtained a US patent covering the analyte-collecting device at the core of its diagnostic cartridge, progress on commercializing new products using that technology and pursuing overseas regulatory approvals also warrants monitoring.
In the LST segment, the next-generation automated cell counter LUNA-III has been recognized with SelectScience's 2025 new product award, expanding global visibility that could support broader overseas sales channel development.
The women's-health digital healthcare brand referenced in recent filings, which combines diagnostic kits, mobile-linked devices, and AI-based personalized services, appears to represent an attempt to extend beyond the core LST/POCT businesses into consumer-facing digital healthcare.
On the earnings front, while the company posted net profit for four consecutive quarters through Q2 2026, the multi-year decline in operating margin makes it important to watch whether upcoming quarters show a genuine recovery in operating profitability rather than continued reliance on non-operating items.
Because both the molecular diagnostics and life science tools end-markets are expanding at a measured pace, individual events such as new product launches or certification milestones could have an outsized impact on reported results.
The current share price trades roughly in line with the company's net asset value, without a pronounced premium or discount to book value evident at this time. The earnings multiple can be read against the backdrop of a return to profit for four consecutive quarters following the Q2 2025 net loss.
That said, given the multi-year decline in operating margin from 21.9% in 2023 to 15.3% in 2025, it is worth distinguishing whether the recent earnings recovery reflects genuine operating improvement or continued reliance on non-operating contributions.
On the dividend front, no recent payout track record has been identified, limiting the extent to which a dividend-yield-based valuation lens can be applied.
Ultimately, the valuation picture for this stock is one that could be read differently depending on how earnings stability and direction are confirmed in upcoming quarterly results.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Annual revenue grew for four consecutive years, from KRW 13.75bn in 2022 to KRW 16.02bn in 2025. The company benefits from two distinct growth pillars—life science tools and molecular diagnostics—reducing reliance on any single product line.
The addition of a women's-health digital healthcare brand referenced in recent filings could further diversify the revenue base.
Following a net loss in Q2 2025, the company posted net income attributable to owners for four straight quarters through Q2 2026. Notably, Q2 2026 net income of KRW 1.75bn was the highest in the period shown. This short-term improvement trend can be read as a positive signal.
The company has obtained GMP conformity certification for its molecular diagnostics manufacturing facility and secured a US patent related to its diagnostic cartridge. Its LUNA-III automated cell counter won a SelectScience 2025 new product award, broadening global recognition. These certifications and accolades could serve as a foundation for expanding overseas sales.
Operating margin has declined for three straight years, from 21.9% in 2023 to 17.6% in 2024 and 15.3% in 2025. This can be interpreted as costs or expense structures expanding alongside revenue growth. If core operating profitability fails to improve, the significance of top-line growth could be limited.
In Q2 2025, the company posted an operating profit of KRW 260mn but a net loss of KRW -117mn, while in Q2 2026 net income of KRW 1.75bn far exceeded operating profit of KRW 644mn. Both instances suggest non-operating items had a substantial effect on results. Such volatility adds to the difficulty of forecasting future earnings.
As a small-cap KOSDAQ name, the stock has a documented history of sharp swings tied to COVID-19 diagnostic-kit themes. Given its relatively small market capitalization, price volatility driven by individual news flow or trading dynamics can be comparatively large. This implies potential for short-term price moves that are disconnected from fundamentals.
A recurring pattern of large quarter-to-quarter gaps between operating profit and net income points to an ongoing risk of results being swayed by non-operating items such as foreign exchange, equity-method gains, or asset valuations.
This is why investors need to examine operating results and net income separately when interpreting performance. If a similar pattern recurs in future quarters, confidence in earnings forecasts could be reduced.
The company competes in an industry category alongside far larger global life science instrument makers such as Thermo Fisher Scientific, Revvity, and Mettler-Toledo. It may be at a disadvantage in terms of economies of scale or R&D investment capacity, which could constrain long-term market share expansion. Maintaining competitiveness in niche product segments remains an ongoing requirement.
If the pace of mass production for molecular diagnostic cartridges or overseas regulatory approvals lags expectations, the commercialization benefits anticipated from GMP certification or the US patent could be delayed.
In-vitro diagnostic devices are subject to varying approval processes across countries, making the timing of overseas market entry uncertain. This translates into uncertainty around when new products will begin contributing meaningfully to revenue.
The Q3 2026 quarterly report is due, providing an opportunity to check whether the gap between operating profit and net income persists and how much the molecular diagnostics segment contributes to revenue.
Investors should watch for disclosures confirming the start of mass production and revenue recognition for the GMP-certified molecular diagnostic cartridge.
Progress on overseas regulatory approvals (such as FDA clearance) for new products leveraging the diagnostic cartridge patent should be tracked.
It will be worth confirming whether new product lines, such as the women's-health digital healthcare brand, begin contributing more meaningfully to revenue.
The 2026 annual business report will offer a chance to see whether the multi-year decline in operating margin reverses.
Aligned Genetics has recorded four consecutive years of revenue growth from 2022 to 2025, built on its two business pillars of life science tools and molecular diagnostics.
However, operating margin declined from the 20% range to the mid-teens over the same period, and a recurring pattern of large gaps between operating profit and net income on a quarterly basis warrants close attention to earnings quality.
The return to net profit for four consecutive quarters from the Q2 2025 loss through Q2 2026 reflects a recent recovery trend, though whether this stems from genuine operating improvement or non-operating contributions needs to be distinguished.
Facts such as GMP certification for the molecular diagnostics manufacturing facility, the related US patent, and the global new-product award for LUNA-III could serve as a foundation for medium- to long-term business expansion.
At the same time, the company competes in an industry category alongside far larger global rivals, which presents a relative disadvantage. Investors will want to continue monitoring whether operating margin rebounds and whether new product lines contribute more meaningfully to revenue in upcoming quarters.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.